- How NICE has applied it’s disease severity modifier.
- Non-profit hospitals and bond ratings.
- Calculating cell & gene therapy breakeven point using RWD.
- Public vs. private Medicaid.
- Supplementing VA with private insurance.
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird...
ByglobalreutersFebruary 21, 2025Hospitals are adopting AI technology more than ever before, but they still...
ByglobalreutersFebruary 21, 2025This fact sheet provides an overview of the history of the Kemp-Kasten...
ByglobalreutersFebruary 21, 2025
Leave a comment